---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-197605"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:37:49.822512+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports positive Phase 1 data for IDE849 in SCLC, positive Phase 2 darovasertib in UM, positive IDE397 combo data

## Summary
- IDE849 (DLL3 ADC) showed 73.2% ORR (52/71) and 47.9% confirmed ORR in SCLC at >=2.4 mg/kg; median PFS 6.7 months.
- Darovasertib neoadjuvant UM trial: 76% (16/21) achieved >=20% tumor shrinkage; 48% had >=20% reduction in simulated radiation dose.
- IDE397 (MAT2A) + Trodelvy in MTAP-del UC: 33% ORR at DL1 (3cPR), 57% ORR at DL2 (3cPR+1uPR); DCR up to 100%.
- Phase 3 OptimUM-10 trial for darovasertib in neoadjuvant primary UM initiated Q2 2025; additional data at ESMO Oct 2025.

## SEC filing metadata
- accession: 0001193125-25-197605
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312525197605/0001193125-25-197605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312525197605/d38716d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-197605
- JSON: https://secwatch.observer/filing/0001193125-25-197605.json
- Plain text: https://secwatch.observer/filing/0001193125-25-197605.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.